BRAF and malignant colon neoplasm: Previous research has reported that cetuximab improves AZD6244 antitumor activity in CRC HT29 cells in vitro and in nude mice by attenuating Her3/Akt pathway activation.[10] In vitro, ERBB3 knockdown decreases cell proliferation, induces apoptosis, and blocks the migration of colon cancer cells.[11] At the same time, in BRAF-V600E mutant colon cancer stem cells (CSCs), HER3/Neuregulin-1β induces cellular proliferation and drug resistance to vemurafenib.[12]